Results 1 to 10 of about 268,816 (213)
Cancers, 2011 Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential ...
Gouw, Launce G +3 more
core +5 more sources
The Oncologist, 2001 Abstract ASCO 2001 was a banner year for innovative systemic therapy for sarcomas. Imatinib mesylate (STI571, GleevecTM) shows clear activity not only in chronic myelogenous leukemia, for which the drug received Food and Drug Administration approval, but also in gastrointestinal stromal tumors as well, by virtue of imatinib mesylate ...
E O., Dickens, J M., McGeeE
openaire +4 more sources
Experimental Hematology & Oncology, 2023 Soft-tissue sarcoma (STS) are a heterogeneous group of rare tumors with different biological behavior that are fatal in more than 40% of cases, due to their metastatic evolution and inadequate treatment options. ATR inhibition already showed an activity,
M Spalato-Ceruso +8 more
doaj +1 more source
, 2011 Sarcomas are a diverse group of malignancies originating in the connective tissue. The approach of a patient with a mass suspect for sarcoma starts with performing a biopsy to obtain tissue for evaluation by pathology. The main role of the current imaging modalities, in general, is to recognize patients with typically benign disease, in whom further ...
Ceyssens, Sarah, Stroobants, Sigrid
openaire +4 more sources
JCO Global Oncology, 2021 PURPOSEIn Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five specialist centers. Many patients are required to travel long distances to access specialist care.
Holly M. McCabe +14 more
doaj +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2010 A 59-year-old white woman, SC, after being treated for pneumonia, presented with an increase in the size of lymph nodes. The immunohistochemical examination diagnosed histiocytic sarcoma. Relapse occurred 12 months after starting chemotherapy. The patient evolved with febrile neutropenia, septic shock and death.
Machado, Eduardo Silva +4 more
openaire +5 more sources
Feasibility study of clinical target volume definition for soft-tissue sarcoma using muscle fiber orientations derived from diffusion tensor imaging [PDF]
, 2022 Objective: Soft-tissue sarcoma spreads preferentially along muscle fibers. We explore the utility of deriving muscle fiber orientations from diffusion tensor MRI (DT-MRI) for defining the boundary of the clinical target volume in muscle tissue. Approach: We recruited eight healthy volunteers to acquire MR images of the left and right thigh. The imaging
arxiv +1 more source
ESMO Open, 2020 Background Imatinib is the standard first-line therapy in metastatic gastrointestinal stromal tumours (GIST). Investigational multi-kinase inhibitors (MKIs) such as nilotinib, dasatinib or masitinib have been tested as first-line therapies in phase II ...
Etienne Rouleau +14 more
doaj +1 more source
Frontiers in Oncology, 2023 BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and ...
Sant P. Chawla +13 more
doaj +1 more source
Uncovering the molecular mechanism for dual effect of ATP on phase separation in FUS solution [PDF]
Sci. Adv. 8, eabo7885 (2022), 2021 Recent studies reported that adenosine triphosphate (ATP) could inhibit as well as enhance the phase separation in prion-like proteins. The molecular mechanism underlying such a puzzling phenomenon remains elusive. Here, taking the fused in sarcoma (FUS) solution as an example, we comprehensively reveal the underlying mechanism by which ATP regulates ...
arxiv +1 more source